Interventional psychiatry is a branch of mental health treatment that uses targeted procedures, rather than daily medications or talk therapy alone, to treat conditions like severe depression, OCD, and suicidal ideation. The term was first coined in 2014 to describe treatments that are more procedural than standard psychiatric care and require specialized training to deliver. Think of it as the psychiatric equivalent of interventional cardiology: instead of relying solely on pills, clinicians use technology to directly influence brain activity.
These treatments are typically reserved for people whose symptoms haven’t improved with conventional approaches. For depression specifically, “treatment-resistant” means a person’s symptoms have not responded to at least two different antidepressant medications, each taken at an adequate dose for four to six weeks.
How It Differs From Traditional Psychiatry
In standard psychiatric care, the main tools are oral medications and psychotherapy. Antidepressants, mood stabilizers, and anti-anxiety drugs work systemically, meaning they circulate throughout your entire body. That’s why they often come with side effects like weight gain, sexual dysfunction, nausea, insomnia, and dry mouth. These medications also take weeks to reach full effect, and finding the right one can involve months of trial and error.
Interventional psychiatry takes a different approach. Instead of flooding the whole body with a drug, these treatments deliver energy or medication directly to the brain or specific neural circuits. The goal is more precise targeting with fewer systemic side effects. The procedures happen in a clinical setting under medical supervision, often on a scheduled basis rather than as a daily at-home routine.
Core Treatments
The field originally centered on two brain stimulation therapies: electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS). It has since expanded to include ketamine-based treatments and implanted devices. Each works differently, but they share a common principle: restoring normal activity in brain circuits that have become dysfunctional.
Transcranial Magnetic Stimulation (TMS)
TMS uses magnetic pulses, similar in strength to an MRI, to stimulate specific areas of the brain’s surface without surgery or sedation. The magnetic field passes through the skull without energy loss and activates targeted regions associated with mood regulation. You sit in a chair, a coil is placed against your head, and the treatment session typically lasts 20 to 40 minutes.
Newer accelerated protocols compress a full course of treatment into just a few days rather than the traditional six weeks. Studies of accelerated deep TMS show an 80% response rate and roughly 50% remission rate within the first month. Some patients in three-session-per-day protocols reached meaningful improvement by day three or four. Side effects are generally mild: headache and scalp discomfort at the stimulation site are most common, and seizures are extremely rare.
Electroconvulsive Therapy (ECT)
ECT is the oldest interventional psychiatric treatment and remains one of the most effective for severe depression, particularly when someone is at immediate risk. Modern ECT bears little resemblance to its historical portrayal. Patients receive general anesthesia and a muscle relaxant, and a brief, controlled electrical current is delivered to the brain to induce a short seizure. The entire procedure takes a few minutes.
The main concern with ECT is cognitive side effects. Patients may experience confusion, disorientation, and short-term memory difficulties lasting hours to weeks after treatment. Some people report longer-lasting memory gaps, particularly for events around the time of treatment. The type and placement of the electrodes matter: bilateral placement tends to cause greater overall cognitive effects, while right-sided unilateral placement is associated more with visual memory changes and generally produces fewer side effects. Despite these tradeoffs, ECT often works when nothing else has.
Ketamine and Esketamine
Ketamine-based treatments represent one of the most significant recent additions to the field. Unlike traditional antidepressants that take weeks to work, ketamine can produce noticeable mood improvement within hours. It works through a completely different brain pathway than standard antidepressants, affecting a signaling system involved in learning, memory, and the formation of new neural connections.
The FDA-approved nasal spray form, esketamine (brand name Spravato), is specifically indicated for treatment-resistant depression and for adults with major depression accompanied by acute suicidal thoughts or behavior. It must be taken alongside a standard oral antidepressant. During the initial four weeks, you visit a clinic twice per week for administration. After that, the frequency drops to once weekly and eventually to every two weeks.
Every session requires a two-hour observation period in the clinic because the medication can cause temporary dissociation, dizziness, elevated blood pressure, and nausea. Your blood pressure is checked before treatment and again about 40 minutes afterward. You cannot drive yourself home. Intravenous ketamine, while not yet FDA-approved for depression specifically, is also used in clinical settings and follows similar monitoring requirements.
Vagus Nerve Stimulation (VNS)
VNS involves surgically implanting a small device under the skin of the chest that sends regular electrical pulses to the brain via the vagus nerve. The FDA approved it in 2005 for adults 18 and older with severe, recurrent depression (unipolar or bipolar) who have failed to respond to at least four antidepressant treatments. It is not approved for psychotic depression. VNS is a longer-term intervention. The device works continuously, and benefits often develop gradually over months.
How These Treatments Work in the Brain
Mental health conditions like depression and OCD involve disrupted communication between specific brain regions. The prefrontal cortex (involved in decision-making and emotional regulation) and the limbic system (which processes emotions) often show weakened or abnormal connectivity in people with these conditions.
Interventional treatments restore this connectivity through several mechanisms. They strengthen the connections between brain cells (a process called neuroplasticity), promote the growth of new neurons and synapses, and regulate key chemical messengers like serotonin and glutamate. Higher-intensity stimulation can reach deeper brain structures through the outer cortex, strengthening connections in the hippocampus, a region critical for memory and mood. Essentially, these therapies help the brain rewire itself in ways that medication alone sometimes cannot achieve.
Who Is Eligible
Interventional treatments are not first-line options. They are typically considered after standard approaches have been tried and found insufficient. For most of these therapies, you would need to demonstrate that at least two antidepressants with different mechanisms of action, taken at appropriate doses for at least four weeks each, did not adequately control your symptoms.
Some nuance exists depending on the situation. For esketamine in someone experiencing acute suicidal thoughts, the threshold may be different. And for VNS, the bar is higher: a history of failing four or more antidepressant interventions is required. Your psychiatrist or primary care provider would document your treatment history, establish baseline symptom scores using a standardized screening tool, and coordinate a treatment plan before starting any interventional procedure.
Insurance and Cost Considerations
Coverage for interventional psychiatry varies significantly by treatment type and insurer. TMS has gained relatively broad insurance acceptance for treatment-resistant depression, though prior authorization is almost always required. Esketamine (Spravato) is covered by many insurance plans, but the twice-weekly clinic visits during the first month add logistical and financial burden even when the drug itself is covered.
Intravenous ketamine has been harder to get covered because it is used off-label for depression. That is starting to change. Some state Medicaid programs now cover IV ketamine with prior authorization, requiring documentation of failed antidepressant trials, a standardized treatment plan, and supervision by a qualified provider. In states or plans without coverage, patients often pay out of pocket, with individual infusion sessions typically running several hundred dollars each.
ECT and VNS, as more established treatments, generally have broader insurance coverage, though VNS requires documentation of extensive treatment failure. Regardless of the specific procedure, expect your insurance company to require detailed records showing what you have already tried, how long you tried it, and why it was not effective.
What a Treatment Course Looks Like
The patient experience varies by modality. TMS is the least disruptive to daily life. You remain fully awake, need no anesthesia, and can drive yourself to and from appointments. A standard course involves daily sessions for several weeks, though accelerated protocols can compress this to under a week. ECT typically involves two to three sessions per week for three to four weeks, each requiring someone to drive you home due to anesthesia.
Ketamine-based treatments fall somewhere in between. The clinic visits are frequent at first and each one takes about two and a half hours including observation time. You will need someone available to take you home. Over time, as you move into the maintenance phase, visits become less frequent. For all of these treatments, they are typically used alongside continued medication and therapy rather than as replacements for them.